The merger will give Biosystems International access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company establish new relationships with university-based proteomics laboratories and pharma and biotech firms.
The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.
The donation will fund research at the Institute for Personalized Cancer Therapy and the Center for Targeted Therapy into more effective drug treatments, including investigations into protein pathway-directed therapies, said an official.
Results from the 94-subject study suggest that the test could be useful in screening high-risk patients for ovarian cancer and possibly even as a screening diagnostic for the general population, a Georgia Tech researcher said.
The center will focus on developing biomarker panels for measuring patient response to drug treatments for lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease, said one of its founders.